FFR is an index of the functional severity of a coronary stenosis that is calculated from pressure measurements taken before and after a narrowing of the arteries during coronary arteriography.
The FFR approach enables an ‘on the spot’ diagnosis for a better assessment as to whether a stent is an appropriate intervention to improve blood circulation in the cardiovascular system.
Opsens Medical Division VP Claude Belleville said the FAME study has been influential in the adoption of FFR as a technique for assessing patients.
"The FFR market, while in its early stages, has been growing exponentially as doctors understand the potential for improved patient outcomes," Belleville said.
Opsens president and CEO Pierre Carrier said the FFR market represents a real and significant opportunity for Opsens and its shareholders.
"We intend to fully exploit this opportunity through the aggressive development of EasyWire through the stages of animal and human testing, and then commercialization," Carrier said.
